218 related articles for article (PubMed ID: 32916177)
1. Renin-angiotensin aldosterone inhibitor use at hospital discharge among patients with moderate to severe acute kidney injury and its association with recurrent acute kidney injury and mortality.
Siew ED; Parr SK; Abdel-Kader K; Perkins AM; Greevy RA; Vincz AJ; Denton J; Wilson OD; Hung AM; Ikizler TA; Robinson-Cohen C; Matheny ME
Kidney Int; 2021 May; 99(5):1202-1212. PubMed ID: 32916177
[TBL] [Abstract][Full Text] [Related]
2. Risk of acute kidney injury by initiation of non-steroidal anti-inflammatory drugs in hospitalised patients treated with diuretics and renin-angiotensin-aldosterone system inhibitors.
Bories M; Bacle A; Gilardi H; Le Corre P
Eur J Hosp Pharm; 2022 Nov; 29(6):359-361. PubMed ID: 33478983
[TBL] [Abstract][Full Text] [Related]
3. Use of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Acute Kidney Disease after an Episode of AKI: A Multicenter Prospective Cohort Study.
Hines A; Li X; Ortiz-Soriano V; Saleh S; Litteral J; Ruiz-Conejo M; Wald R; Silver SA; Neyra JA
Am J Nephrol; 2020; 51(4):266-275. PubMed ID: 32088714
[TBL] [Abstract][Full Text] [Related]
4. Prospective Cohort Study of Renin-Angiotensin System Blocker Usage after Hospitalized Acute Kidney Injury.
Brar S; Liu KD; Go AS; Hsu RK; Chinchilli VM; Coca SG; Garg AX; Himmelfarb J; Ikizler TA; Kaufman J; Kimmel PL; Parikh CR; Siew ED; Ware LB; Zeng H; Hsu CY; ;
Clin J Am Soc Nephrol; 2020 Dec; 16(1):26-36. PubMed ID: 33272913
[TBL] [Abstract][Full Text] [Related]
5. Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes.
An J; Zhou H; Ni L; Harrision TN; Wei R; Agiro A; Brahmbhatt YG; Oluwatosin Y; Schilling CG; Sim JJ
Am J Nephrol; 2023; 54(7-8):258-267. PubMed ID: 37231821
[TBL] [Abstract][Full Text] [Related]
6. Renin-Angiotensin System Blockade after Acute Kidney Injury (AKI) and Risk of Recurrent AKI.
Hsu CY; Liu KD; Yang J; Glidden DV; Tan TC; Pravoverov L; Zheng S; Go AS
Clin J Am Soc Nephrol; 2020 Jan; 15(1):26-34. PubMed ID: 31843974
[TBL] [Abstract][Full Text] [Related]
7. Stopping renin-angiotensin system blockers after acute kidney injury and risk of adverse outcomes: parallel population-based cohort studies in English and Swedish routine care.
Bidulka P; Fu EL; Leyrat C; Kalogirou F; McAllister KSL; Kingdon EJ; Mansfield KE; Iwagami M; Smeeth L; Clase CM; Bhaskaran K; van Diepen M; Carrero JJ; Nitsch D; Tomlinson LA
BMC Med; 2020 Jul; 18(1):195. PubMed ID: 32723383
[TBL] [Abstract][Full Text] [Related]
8. Estimating the risk of acute kidney injury associated with use of diuretics and renin angiotensin aldosterone system inhibitors: A population based cohort study using the clinical practice research datalink.
Scott J; Jones T; Redaniel MT; May MT; Ben-Shlomo Y; Caskey F
BMC Nephrol; 2019 Dec; 20(1):481. PubMed ID: 31888533
[TBL] [Abstract][Full Text] [Related]
9. Real-World Associations of Renin-Angiotensin-Aldosterone System Inhibitor Dose, Hyperkalemia, and Adverse Clinical Outcomes in a Cohort of Patients With New-Onset Chronic Kidney Disease or Heart Failure in the United Kingdom.
Linde C; Bakhai A; Furuland H; Evans M; McEwan P; Ayoubkhani D; Qin L
J Am Heart Assoc; 2019 Nov; 8(22):e012655. PubMed ID: 31711387
[TBL] [Abstract][Full Text] [Related]
10. Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry.
Rossignol P; Lainscak M; Crespo-Leiro MG; Laroche C; Piepoli MF; Filippatos G; Rosano GMC; Savarese G; Anker SD; Seferovic PM; Ruschitzka F; Coats AJS; Mebazaa A; McDonagh T; Sahuquillo A; Penco M; Maggioni AP; Lund LH;
Eur J Heart Fail; 2020 Aug; 22(8):1378-1389. PubMed ID: 32243669
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19.
Sharma A; Elharram M; Afilalo J; Flannery A; Afilalo M; Tselios C; Ni J; Ezekowitz JA; Cheng MP; Ambrosy AP; Zannad F; Brophy JM; Giannetti N; Bessissow A; Kronfli N; Marelli A; Aziz H; Alqahtani M; Aflaki M; Craig M; Lopes RD; Ferreira JP
Am Heart J; 2022 May; 247():76-89. PubMed ID: 35143744
[TBL] [Abstract][Full Text] [Related]
12. Impact of renin-angiotensin system inhibitors on long-term clinical outcomes of patients with rheumatic heart disease.
Liu C; Lai Y; Wu D; Fu R; Li Y; Li H; Guan T; Shen Y
ESC Heart Fail; 2021 Dec; 8(6):5338-5351. PubMed ID: 34545695
[TBL] [Abstract][Full Text] [Related]
13. Outcomes in patients with cardiometabolic disease who develop hyperkalemia while treated with a renin-angiotensin-aldosterone system inhibitor.
Johnson M; Morrison FJ; McMahon G; Su M; Turchin A
Am Heart J; 2023 Apr; 258():49-59. PubMed ID: 36642227
[TBL] [Abstract][Full Text] [Related]
14. Maintaining Renin-Angiotensin-Aldosterone System Inhibitor Treatment with Patiromer in Hyperkalaemic Chronic Kidney Disease Patients: Comparison of a Propensity-Matched Real-World Population with AMETHYST-DN.
Chinnadurai R; Rengarajan S; Budden JJ; Quinn CM; Kalra PA
Am J Nephrol; 2023; 54(9-10):408-415. PubMed ID: 37725919
[TBL] [Abstract][Full Text] [Related]
15. Adverse effects during treatment with renin-angiotensin-aldosterone system inhibitors; should we stay or should we stop?
Leon SJ; Carrero JJ
Curr Opin Nephrol Hypertens; 2023 May; 32(3):290-296. PubMed ID: 36811640
[TBL] [Abstract][Full Text] [Related]
16. Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence.
Hundemer GL; Talarico R; Tangri N; Leon SJ; Bota SE; Rhodes E; Knoll GA; Sood MM
Clin J Am Soc Nephrol; 2021 Mar; 16(3):365-373. PubMed ID: 33608262
[TBL] [Abstract][Full Text] [Related]
17. The effect of renin-angiotensin-aldosterone system inhibitors on continuous and binary kidney outcomes in subgroups of patients with diabetes: a meta-analysis of randomized clinical trials.
Alsalemi N; Sadowski CA; Elftouh N; Louis M; Kilpatrick K; Houle SKD; Lafrance JP
BMC Nephrol; 2022 Apr; 23(1):161. PubMed ID: 35484505
[TBL] [Abstract][Full Text] [Related]
18. DOPPS data suggest a possible survival benefit of renin angiotensin-aldosterone system inhibitors and other antihypertensive medications for hemodialysis patients.
Karaboyas A; Xu H; Morgenstern H; Locatelli F; Jadoul M; Nitta K; Dasgupta I; Tentori F; Port FK; Robinson BM
Kidney Int; 2018 Sep; 94(3):589-598. PubMed ID: 29908836
[TBL] [Abstract][Full Text] [Related]
19. The Effect of Renin-Angiotensin-Aldosterone System Inhibitors on Outcomes of Patients Treated with Immune Checkpoint Inhibitors: a Retrospective Cohort Study.
Chiang CH; Wang SS; Chang YC; Chiang CH; Chen CY; Chen YJ; See XY; Peng CY; Hsia YP; Chiang CH; Peng CM
Clin Oncol (R Coll Radiol); 2023 Jul; 35(7):446-453. PubMed ID: 36894383
[TBL] [Abstract][Full Text] [Related]
20. Processes of Care After Hospital Discharge for Survivors of Acute Kidney Injury: A Population-Based Cohort Study.
Brar S; Ye F; James MT; Harrison TG; Pannu N;
Am J Kidney Dis; 2024 Feb; 83(2):216-228. PubMed ID: 37734688
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
